Olema Pharmaceuticals, Inc.·4

Mar 5, 8:00 PM ET

Mitchell Shawnte 4

4 · Olema Pharmaceuticals, Inc. · Filed Mar 5, 2026

Insider Transaction Report

Form 4
Period: 2026-03-03
Mitchell Shawnte
CHIEF LEGAL OFFICER
Transactions
  • Exercise/Conversion

    Common Stock

    2026-03-03$4.37/sh+15,000$65,55015,000 total
  • Sale

    Common Stock

    [F1]
    2026-03-03$23.01/sh15,000$345,1500 total
  • Exercise/Conversion

    Common Stock

    2026-03-04$4.37/sh+25,000$109,25025,000 total
  • Sale

    Common Stock

    [F2]
    2026-03-04$24.25/sh24,767$600,600233 total
  • Sale

    Comon Stock

    [F3]
    2026-03-04$24.69/sh233$5,7530 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    [F4]
    2026-03-0315,000435,000 total
    Exercise: $4.37Exp: 2035-02-27Common Stock (15,000 underlying)
  • Exercise/Conversion

    Stock Option (Right to Buy)

    [F4]
    2026-03-0425,000410,000 total
    Exercise: $4.37Exp: 2035-02-27Common Stock (25,000 underlying)
Footnotes (4)
  • [F1]The weighted average sale price for the transaction reported was $23.01, and the range of prices were between $22.89 and $23.19. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
  • [F2]The weighted average sale price for the transaction reported was $24.25, and the range of prices were between $23.68 and $24.64. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
  • [F3]The weighted average sale price for the transaction reported was $24.69, and the range of prices were between $24.68 and $24.70. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
  • [F4]25% of the shares subject to the option vest on February 28, 2026 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.
Signature
/s/ Shawnte Mitchell|2026-03-05

Documents

1 file
  • 4
    form4-03052026_080301.xmlPrimary